AUCTORES
Globalize your Research
Case report | DOI: https://doi.org/10.31579/2578-8868/308
1Department of Physiology, Health and Medical University, Olympischer Weg 1, D-14771 Potsdam, Germany.
2International Neuroscience Institute (INI), Rudolf-Pichlmayr-Str. 4, D-30625 Hannover, Germany.
*Corresponding Author: Gerhard Franz Walter, International Neuroscience Institute (INI), Rudolf-Pichlmayr-Str. 4, D-30625 Hannover, Germany.
Citation: Wilhelm J. Walter, Gerhard F. Walter, (2024), mRNA: A Physiological Multipurpose Tool for Hitherto Hard-to-treat Neurological and Neuro-Ophthalmological Diseases, J. Neuroscience and Neurological Surgery, 14(2); DOI:10.31579/2578-8868/308
Copyright: © 2024, Gerhard Franz Walter. This is an open-access article distributed under the terms of The Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Received: 01 March 2024 | Accepted: 18 March 2024 | Published: 29 March 2024
Keywords: organ-specific malfunctioning proteins; mrna-technology; mrna-vaccination for infectious diseases; mrna cancer therapy
Interdisciplinary translational research between physiologists and clinicians based on mRNA technology has opened and shall open treatment perspectives for a broad range of diseases, many of them hitherto hard to treat or not treatable at all. In this overview, various options for applications of mRNA technology are presented for the treatment of quite different neurological and neuro-ophthalmological disease categories such as metabolic and neurodegenerative diseases, infectious diseases, and tumors, illustrated by a few selected examples of current clinical trials and experimental approaches. mRNA technology allows for developing tailor-made individualized therapies by which the body may even produce the remedies itself according to the physiological recipe of the mRNA assembly instructions.
Aim of this overview is to interest ophthalmologists and clinical neuroscientists in the immense therapeutic novelties brought forth by mRNA-technology.
Malfunctioning proteins play a role in a broad spectrum of diseases. When our immune system sends antibodies into the battle against pathogens, it commands nothing more than an army of protein fabrics. From birth through all of life, everyone carries a potential multipurpose tool in the cell nuclei of our body: the messenger ribonucleic acid (mRNA). mRNA as a kind of physiological multipurpose tool to develop tailor-made therapies. In principle, mRNA is an optimal tool for multipurpose approaches in medicine because it holds the physiological blueprint, a kind of software program, for the realm of proteins.
In 2023, the World Health Organization (WHO) Science Council took an initial step towards assessing the potential of mRNA technology for improving global health by conducting an independent review of its role in the development of vaccines for the prevention of infectious diseases and virus-induced cancers. This report summarizes the advantages and limitations of the technology and provides recommendations to focus research efforts [1].
Physiological principles for mRNA as a tool in the manufacture of proteins
The double-helical structure of DNA is the carrier of genetic information and the basis for heritability. That a gene expresses itself and a protein can be produced, transcription, splicing and translation are necessary, the underlying physiology is shortly summarized as follows:
Within the cell nucleus, in DNA, the nucleobases adenine (A), cytosine (C), guanine (G), and thymine (T) are found. The sequence of the four bases of DNA encodes the genetic information, which is why the four letters A, C, G, and T can be regarded as the “alphabet of life”. The nucleobases A-C and G-T form complementary base pairs in the two strands of DNA. The human genome is made up of approximately 3.2 billion base pairs.
First, the double-stranded DNA is split into two single strands. One DNA strand serving as a template for complementary base pairing is transcribed to a ribonucleic acid (RNA) molecule, the precursor-messenger RNA (pre-mRNA) molecule. In RNA, the nucleobase uracil (U) replaces thymine (T), distinguished from thymine only by one methyl group.
Second, during RNA exon splicing the pre-mRNA transcript is transformed into messenger mRNA. All the non-coding regions of RNA, the introns, are removed and the coding regions, the exons, are spliced together. Splicing is necessary, so that, during translation, an mRNA molecule can be translated into a protein.
Third, the RNA-adapted G-C/A-U message of the genetic code is messaged by mRNA from the nucleus to the cytoplasm. The single-stranded mRNA is translated from the “nucleotide language” into the “amino acid language”. Such as words in a book, the mRNA is read in one direction, thereby, translating the genetic code of the DNA sequence to the amino acid sequence in proteins. Triplets are composed of three nucleobases, deoxyribose or ribose and a phosphate group forming together a nucleotide (“the word in the nucleotide language”), thus, a codon for a codon-specific different amino acid (“the word in the amino acid language”) in the cytoplasm. Therefore, ribosomes in the cytoplasm are needed. Ribosomes consist of two subunits: one subunit decodes the mRNA, reading the nucleotide that corresponds to a specific amino acid; the other subunit forms the peptide bonds. The sequence of nucleotides (“the sentence in the nucleotide language”) is translated into a sequence of amino acids which form in that way a chain of amino acids, the specific protein (“the sentence of the amino acid language”), thus, the structure of DNA determines the structure of proteins. mRNA is decoded with the help of transfer ribonucleic acid (tRNA). tRNA transfers one after the other corresponding amino acid to the end of the amino acid chain until the entire sequence is translated into the specific protein.
Methodological remarks on mRNA technology
Initially, the inflammatory nature of the mRNAs limited the in vivo use. Robert W. Malone for transfection modalities for delivery of mRNA [2], and Katalin Karikó and Drew Weissman deserve special recognition for the development of the mRNA technology. The latter could show that naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA [3]. Replacing uridine with pseudo-uridine made the mRNA non-immunogenic, with increased translational capacity and biological stability [4]. It was not unexpected that the 2023 Nobel Prize in Physiology or Medicine was awarded jointly to Katalin Karikó and Drew Weissman.
The labile nature of the mRNA is ideal for a transient production of a viral antigen, to trigger an effective antibody and cellular immune response. mRNA transcribed in vitro can serve as a template for specific proteins of infectious agents such as viruses and, thereby, allow for a novel approach for vaccination. Inherent challenges are related to controlling the translational efficacy and immunogenicity.
mRNA transcribed in vitro can also be engineered to transiently express proteins and, thereby, replace or supplement proteins that are impaired due to gene mutations. Because insufficiently functioning proteins can be produced in specific cells, there is a critical need to develop organ/cell-specific delivery strategies to reach the full potential of genomic medicines. The development of CRISPR/Cas-based gene editing [5] and mRNA-based gene replacement technologies opened the way towards new therapies for currently untreatable genetic diseases. Novel approaches included in vitro-transcribed mRNA-based generation of pluripotent stem cells and genome engineering using in vitro transcribed mRNA-encoded designer nucleases [6].
A major challenge of gene sequence delivery is to achieve the most complete transfection of the target structure while avoiding leakage into neighboring regions or perivascular spaces. In vivo vector-mediated delivery encompasses different viral and non-viral (particle-mediated gene delivery, plasmid transfection) strategies, none of them universally applicable, e.g., lentiviral vectors bear a mutagenic risk, adeno-associated virus vectors possess a specific tropism for different cell types, including neurotropism. RNA interference may reversibly silence any gene. Delivery systems, including particle-mediated gene delivery through lipid nanoparticles and small interfering RNA (siRNA) conjugates, are required to transport siRNA to the site of action in the cells of target tissues [7].
A novel experimental approach applicable to various nanoparticle systems is termed Selective ORgan Targeting (SORT) and allows nanoparticles to be systematically engineered for accurate delivery of diverse cargoes, including mRNA and Cas9 mRNA complexes, to the lungs, spleens, and livers of mice following intravenous administration. The addition of the supplemental “SORT molecule” precisely alters the in vivo RNA delivery profile and mediates tissue-specific gene delivery and editing [8].
Another novel approach is to process and pack mRNAs into mature ribonucleoprotein complexes (mRNPs), recognized by the essential transcription–export complex (TREX) for nuclear export. mRNPs are recognized through multivalent interactions between the TREX subunit ALYREF and mRNP-bound exon junction complexes. Exon junction complexes can multimerize through ALYREF, which suggests a mechanism for mRNP organization. Endogenous mRNPs form compact globules that are coated by multiple TREX complexes [9].
mRNA treatment for malfunctioning proteins
Brain: Huntingtin protein
Huntington's disease is an autosomal-dominant neurodegenerative disease caused by a CAG trinucleotide repeat expansion in the exon 1 of the huntingtin (HTT) gene. If a child inherits the mutated gene, the disease usually does not occur until adulthood, and then leads to progressing involuntary, sporadic jerking or spasmodic movements (chorea and athetosis), and mental deterioration. So, for children in Huntington-families an early mRNA-therapy could prevent the severe course.
The caudate nucleus of the striatum of the brain is dramatically affected prior to symptom onset, eventually leading to massive bilateral atrophic degeneration of both caudate nuclei (figure 1).
Figure 1: Bilateral atrophic degeneration of the caudate nuclei in Huntington's disease.
Since mutant huntingtin protein is the root cause of Huntington's disease, huntingtin protein-lowering strategies are a focus of therapeutic approaches. Oligonucleotide-based therapeutic approaches using siRNAs and antisense oligonucleotides designed to specifically silence mutant huntingtin may be a novel therapeutic strategy. A clinical trial (ClinicalTrials.gov Identifier: NCT02519036.) used IONIS-HTTRx (Ionis Pharmaceuticals and F. Hoffmann-La Roche), an antisense oligonucleotide designed to inhibit HTT mRNA and thereby reduce concentrations of mutant huntingtin protein. Intrathecal administration of IONIS-HTTRx to patients with early Huntington's disease induce a dose-dependent reduction in concentrations of mutant huntingtin protein [10]. Further, a synthetic physiological strategy was proposed that integrates the naturally existing exosome-circulating system with artificial genetic circuits for self-assembly and delivery of mutant huntingtin-silencing siRNA to the brain cortex and striatum [11].
These approaches target full-length HTT alone and would not be expected to reduce pathogenic exon 1 HTT levels. It could be shown in knock-in mouse models that HTT mRNA carrying an expanded CAG repeat was incompletely spliced to generate HTT1a, an exon 1-only transcript, which was translated to produce the highly aggregation-prone and pathogenic exon 1 HTT protein. This could also be detected in patient cell lines and post-mortem brains. To extend these findings to a model system expressing human HTT, a model was established with YAC128 mice that are transgenic for a yeast artificial chromosome carrying human HTT with an expanded CAG repeat. The HTT1a transcript could be detected throughout the brains of YAC128 mice. Homogeneous time-resolved fluorescence analysis demonstrated that the HTT1a transcript had been translated to produce the exon 1 HTT protein. The levels of exon 1 HTT in YAC128 mice correlated with HTT aggregation, supportive of the hypothesis that exon 1 HTT may initiate the aggregation process [12]. Therefore, it is important that the effects of HTT-lowering strategies on the subcellular levels of all HTT transcripts and their various HTT protein isoforms are understood.
Nerve cells of the retina: All-trans retinyl ester isomerase
The visual cycle operates via an isomerase acting on all-trans retinol in the pigment epithelium [13]. The sight-threatening autosomal recessive genetic disorder RPE65-associated inherited retinal disease is caused by biallelic mutations in the RPE65 gene, which encodes the all-trans retinyl ester isomerase, an enzyme critical to the visual cycle. This severe form of rod cone-mediated retinal disease eventually progresses to complete blindness, so early treatment – which should be possible in inherited cases – may be especially helpful (figure 2).
Figure 2: Mild damage retinal degeneration, stage B [14], with a favorable benefit-to-risk profile for treatment (hematoxylin-eosin),
Ocular gene therapy has become an option for treatment, in which a recombinant adeno-associated viral vector serotype 2 (AAV2) gene replacement therapy produces an encouraging outcome. Clinical trials (Study of efficacy and safety of Voretigene Neparvovec in Japanese patients with biallelic RPE65 mutation-associated retinal dystrophy; ClinicalTrials.gov Identifier: NCT04516369) confirmed the safety, durable efficacy, and favorable benefit-to-risk profile of Voretigene Neparvovec (LUXTURNA™; Spark Therapeutics Inc, Philadelphia, PA, USA, Novartis, Basel, Switzerland), administered as a one-time subretinal injection, in improving retinal and visual function. Voretigene Neparvovec received marketing authorization from the US and the European Union in 2018 for the treatment of adult and pediatric patients with vision loss due to inherited retinal disease related to confirmed RPE65 biallelic mutations and who still have sufficient viable retinal cells [15-17].
mRNA technology for the development of vaccines against infectious diseases
Herpes zoster (varicella-zoster virus)
Herpes zoster affects millions of people around the world each year and may sometimes take a severe course (figure 3).
Figure 3: Fatal supraorbital zoster ophthalmicus (left) caused by varicella-zoster-virus infection of the ganglion Gasseri of the trigeminal nerve with lymphocytic infiltration (right; Masson-trichrome)
Recent developments are reported by the pharmaceutical industry, e.g., by Pfizer Inc. and BionTechSE announcing the start of a Phase 1/2 multicenter, randomized, controlled, dose-selection study (ClinicalTrials.gov Identifier: NCT05703607) enrolling up to 900 healthy volunteers 50 through 69 years of age for exploring the safety, tolerability, and immunogenicity of mRNA vaccine candidates against herpes zoster [18]
Rabies (lyssaviruses, including the rabies virus)
Rabies remains a lethal zoonotic disease. The rabies virus produces ribonuclear proteins in the form of intracellular Negri bodies (figure 4). Results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding the rabies virus glycoprotein (CV7201) are reported (ClinicalTrials.gov Identifier: NCT02241135) and show that this candidate vaccine can induce functional antibodies [19]. Another mRNA vaccine construct (LVRNA001) expressing the rabies virus glycoprotein (RABV-G) provided protection against rabies infection in both mice and dogs [20].
Figure 4: Eosinophilic Negri body (arrow) in a Purkinje cell of the cerebellar cortex, typical for rabies infection of the brain (hematoxylin-eosin).
Malaria
The World Health Organization estimated that there were over 247 million cases of malaria (figure 5) and 619,000 associated deaths in 2021 [21].
Figure 5. Malaria pigment (black) in capillaries of the brain (hematoxylin-eosin). Malaria pigment or hemozoin is an iron–porphyrin–proteinoid complex formed by the parasite Plasmodium sp. from the breakdown of hemoglobin.
The different approaches to provide more effective malaria vaccines – “from the past towards the mRNA vaccine era” – were recently summarized [22]. The circumsporozoite protein (CSP), expressed at the surface of sporozoites of different Plasmodium species, has been identified as a major immunogen. For example, in a double-blind, randomized, controlled, phase 2b trial (ClinicalTrials.gov Identifier: NCT03896724), the circumsporozoite protein-based vaccine R21, with two different doses of adjuvant Matrix-M (MM), was given to children in Burkina Faso [23]. At its regular biannual meeting held in September 2023, the World Health Organization has recommended R21/Matrix-M vaccine for the prevention of malaria in children [24]. The R21 vaccine is the second malaria vaccine recommended by WHO, following the RTS,S/AS01 vaccine, which received a WHO recommendation in 2021.
mRNA technology for new therapies against cancer
Tumor cell-specific protein expression patterns that could serve as a starting point for mRNA treatments. These treatments ought to alert the patient's immune system to proteins that are carrying the cancer-typical alterations.
After decoding the genetic code of a surgical or bioptic tumor sample, an mRNA working copy of it is introduced into the patient’s cell plasma, and eventually, the body now produces exactly those proteins that allow the immune system to recognize and attack the actual tumor cells. In a personalized form of immunotherapy, mRNA is immediately inserted into the patient's own dendritic cells. which initiate immune responses and give the correct instructions on which proteins should be targeted [25].
Glioblastoma
Notwithstanding various treatment approaches in the last decades, glioblastoma multiforme still has a catastrophic survival rate (figure 6). mRNA-technology may open a way to develop special vaccines for glioblastoma and other hard-to-treat gliomas.
Figure 6: Fatal “butterfly” glioblastoma multiforme with diffuse growth via the corpus callosum and large tumor necroses.
In an experimental study, mouse and human mRNA-based multifunctional T cells were generated co-expressing a multitargeting chimeric antigen receptor (CAR) based on the natural killer group 2D (NKG2D) receptor and the proinflammatory cytokines IL12 and IFNα2. Multifunctional CAR T cells demonstrated increased activity of attacking in vitro and in vivo in three orthotopic immunocompetent mouse glioma models without signs of toxicity [26]. Gene expression profiles can identify effective antigens. There exist several immune subtypes of glioma, each one linked to unique prognoses and genetic/immune-modulatory changes. Patients with immune-active and immune-suppressive phenotypes were found to respond better to mRNA vaccines [27].
By using a microfluidic electroporation in which a combination of nano- and milli-second pulses produces IFN-γ mRNA-loaded small extracellular vesicles (sEVs) with CD64 overexpressed on their surface. These immunogenic sEVs preferentially target glioblastoma cells and generate potent anti-tumor activities in vivo, including against tumors intrinsically resistant to immunotherapy [28].
Uveal melanoma
Melanoma is one of the most aggressive and therapy-resistant cancers, primarily found in the Caucasian population with susceptibility factors including fair skin, light eye color, and inability to tan. Ocular melanoma is the most common primary eye tumor in adults (figure 7) metastasizing in up to 50% of cases.
Figure 7: Intraocular uveal melanoma (arrow) located in the choroid.
The efficacy of an mRNA vaccine was tested in an aggressive B16F10 melanoma model of the mouse. A strong CD 8 T cell activation was observed after a single immunization. Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage and extended the overall survival of the treated mice [29].
In patients with high-risk melanoma, an efficacy study – KEYNOTE-942 (ClinicalTrials.gov Identifier: NCT03897881) – of adjuvant treatment with the personalized cancer vaccine mRNA-4157 and Pembrolizumab was performed, and specific immune responses have been observed. The KEYNOTE-942 trial may establish the incorporation of the mRNA-4157/V940 vaccine into the melanoma treatment [30]
Gene therapy and in particular mRNA therapy are at an inflection point [31]. If it becomes more and more possible to intervene in a targeted manner in the realm of proteins, therapeutic options for disease in the broadest sense can be envisaged, and it does not seem exaggerated to assume that a physiological principle opens the door for a new form of medicine to target a multitude of diseases. mRNA represents an almost universal tool for developing tailor-made therapies.
The authors declare that they have no conflict of interests.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
